Cardiovascular co-morbidity in rheumatic diseases

Carl Turesson, L. T H Jacobsson, Eric Lawrence Matteson

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Patients with rheumatic disorders have an increased risk of cardiovascular disease (CVD). This excess co-morbidity is not fully explained by traditional risk factors. Disease severity is a major risk factor for CVD in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Shared disease mechanisms in atherosclerosis and rheumatic disorders include immune dysregulation and inflammatory pathways, which are potential targets for therapy. Lessons from RA and SLE may have implications for future research on the pathogenesis of atherosclerotic vascular disease in general. Recent data indicate that suppression of inflammation reduces the risk of CVD morbidity and mortality in patients with severe RA. The modest, but clinically relevant, efficacy of atorvastatin treatment in RA adds to the evidence for important anti-inflammatory properties for statins. There is increased recognition of the need for structured preventive strategies to reduce the risk of CVD in patients with rheumatic disease. Such strategies should be based on insights into the role of inflammation in CVD, as well as optimal management of life style related risk factors. In this review, the research agenda for understanding and preventing CVD co-morbidity in patients with rheumatic disorders is discussed.

Original languageEnglish (US)
Pages (from-to)605-614
Number of pages10
JournalVascular Health and Risk Management
Volume4
Issue number3
StatePublished - 2008

Fingerprint

Rheumatic Diseases
Cardiovascular Diseases
Morbidity
Rheumatoid Arthritis
Systemic Lupus Erythematosus
Inflammation
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Immune System Diseases
Vascular Diseases
Life Style
Atherosclerosis
Anti-Inflammatory Agents
Mortality
Research

Keywords

  • Cardiovascular disease
  • Inflammation
  • Rheumatoid arthritis
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hematology
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health

Cite this

Cardiovascular co-morbidity in rheumatic diseases. / Turesson, Carl; Jacobsson, L. T H; Matteson, Eric Lawrence.

In: Vascular Health and Risk Management, Vol. 4, No. 3, 2008, p. 605-614.

Research output: Contribution to journalArticle

Turesson, C, Jacobsson, LTH & Matteson, EL 2008, 'Cardiovascular co-morbidity in rheumatic diseases', Vascular Health and Risk Management, vol. 4, no. 3, pp. 605-614.
Turesson, Carl ; Jacobsson, L. T H ; Matteson, Eric Lawrence. / Cardiovascular co-morbidity in rheumatic diseases. In: Vascular Health and Risk Management. 2008 ; Vol. 4, No. 3. pp. 605-614.
@article{f42d97b949f8471282c8d31a434308dd,
title = "Cardiovascular co-morbidity in rheumatic diseases",
abstract = "Patients with rheumatic disorders have an increased risk of cardiovascular disease (CVD). This excess co-morbidity is not fully explained by traditional risk factors. Disease severity is a major risk factor for CVD in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Shared disease mechanisms in atherosclerosis and rheumatic disorders include immune dysregulation and inflammatory pathways, which are potential targets for therapy. Lessons from RA and SLE may have implications for future research on the pathogenesis of atherosclerotic vascular disease in general. Recent data indicate that suppression of inflammation reduces the risk of CVD morbidity and mortality in patients with severe RA. The modest, but clinically relevant, efficacy of atorvastatin treatment in RA adds to the evidence for important anti-inflammatory properties for statins. There is increased recognition of the need for structured preventive strategies to reduce the risk of CVD in patients with rheumatic disease. Such strategies should be based on insights into the role of inflammation in CVD, as well as optimal management of life style related risk factors. In this review, the research agenda for understanding and preventing CVD co-morbidity in patients with rheumatic disorders is discussed.",
keywords = "Cardiovascular disease, Inflammation, Rheumatoid arthritis, Systemic lupus erythematosus",
author = "Carl Turesson and Jacobsson, {L. T H} and Matteson, {Eric Lawrence}",
year = "2008",
language = "English (US)",
volume = "4",
pages = "605--614",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",
number = "3",

}

TY - JOUR

T1 - Cardiovascular co-morbidity in rheumatic diseases

AU - Turesson, Carl

AU - Jacobsson, L. T H

AU - Matteson, Eric Lawrence

PY - 2008

Y1 - 2008

N2 - Patients with rheumatic disorders have an increased risk of cardiovascular disease (CVD). This excess co-morbidity is not fully explained by traditional risk factors. Disease severity is a major risk factor for CVD in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Shared disease mechanisms in atherosclerosis and rheumatic disorders include immune dysregulation and inflammatory pathways, which are potential targets for therapy. Lessons from RA and SLE may have implications for future research on the pathogenesis of atherosclerotic vascular disease in general. Recent data indicate that suppression of inflammation reduces the risk of CVD morbidity and mortality in patients with severe RA. The modest, but clinically relevant, efficacy of atorvastatin treatment in RA adds to the evidence for important anti-inflammatory properties for statins. There is increased recognition of the need for structured preventive strategies to reduce the risk of CVD in patients with rheumatic disease. Such strategies should be based on insights into the role of inflammation in CVD, as well as optimal management of life style related risk factors. In this review, the research agenda for understanding and preventing CVD co-morbidity in patients with rheumatic disorders is discussed.

AB - Patients with rheumatic disorders have an increased risk of cardiovascular disease (CVD). This excess co-morbidity is not fully explained by traditional risk factors. Disease severity is a major risk factor for CVD in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Shared disease mechanisms in atherosclerosis and rheumatic disorders include immune dysregulation and inflammatory pathways, which are potential targets for therapy. Lessons from RA and SLE may have implications for future research on the pathogenesis of atherosclerotic vascular disease in general. Recent data indicate that suppression of inflammation reduces the risk of CVD morbidity and mortality in patients with severe RA. The modest, but clinically relevant, efficacy of atorvastatin treatment in RA adds to the evidence for important anti-inflammatory properties for statins. There is increased recognition of the need for structured preventive strategies to reduce the risk of CVD in patients with rheumatic disease. Such strategies should be based on insights into the role of inflammation in CVD, as well as optimal management of life style related risk factors. In this review, the research agenda for understanding and preventing CVD co-morbidity in patients with rheumatic disorders is discussed.

KW - Cardiovascular disease

KW - Inflammation

KW - Rheumatoid arthritis

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=48049110032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48049110032&partnerID=8YFLogxK

M3 - Article

C2 - 18827910

AN - SCOPUS:48049110032

VL - 4

SP - 605

EP - 614

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

IS - 3

ER -